Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Nuvectis Pharma, Inc. (NVCT) had Stock-Based Compensation of $3.10M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-6.33M |
|
-- |
|
-- |
|
$6.59M |
|
$-6.59M |
|
$0.26M |
|
$-6.33M |
|
$-6.33M |
|
$-6.33M |
|
$-6.33M |
|
$-6.33M |
|
$-6.33M |
|
$-6.59M |
|
$-6.59M |
|
21.37M |
|
21.37M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$27.01M |
|
-- |
|
-- |
|
$27.01M |
|
$10.13M |
|
-- |
|
-- |
|
$10.13M |
|
$16.87M |
|
$16.87M |
|
$16.87M |
|
23.88M |
|
| Cash Flow Statement Financials | |
$-7.54M |
|
-- |
|
$15.80M |
|
$18.53M |
|
$26.79M |
|
$8.26M |
|
|
Stock-Based Compensation |
$3.10M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-37.54% |
|
-37.54% |
|
-23.45% |
|
-37.54% |
|
$0.71 |
|
$-0.35 |
|
$-0.35 |
|